Neoadjuvant Therapy with Disitamab Vedotin in Treating Muscle-Invasive Bladder Cancer: A Case Report

    January 2022 in “ SSRN Electronic Journal ”
    Hai Huang, Zhi Chen, Yucong Zhang, Xing Zeng, Zhiquan Hu, Chunguang Yang
    TLDR Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.
    This case report described a 68-year-old man with muscle-invasive bladder cancer (MIBC) and severe renal insufficiency who was treated with neoadjuvant therapy using gemcitabine and Disitamab Vedotin (DV) due to intolerance to platinum-based regimens. The patient received three cycles of treatment, resulting in a significant reduction of lesions without any aggravation in blood test results or significant abnormal symptoms. Postoperative analysis showed increased HER2 expression. The study concluded that gemcitabine combined with DV was effective and safe for this patient, suggesting the need for further clinical studies with more patients to validate these findings.
    Discuss this study in the Community →